Lorena Gonzalez-Mendez
Overview
Explore the profile of Lorena Gonzalez-Mendez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diaz-Tejedor A, Rodriguez-Ubreva J, Ciudad L, Lorenzo-Mohamed M, Gonzalez-Rodriguez M, Castellanos B, et al.
Int J Mol Sci
. 2024 May;
25(9).
PMID: 38731936
Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of...
2.
Algarin E, Quwaider D, Campos-Laborie F, Diaz-Tejedor A, Mogollon P, Vuelta E, et al.
Cells
. 2021 Apr;
10(3).
PMID: 33806619
BH3-mimetics targeting anti-apoptotic proteins such as MCL-1 (S63845) or BCL-2 (venetoclax) are currently being evaluated as effective therapies for the treatment of multiple myeloma (MM). Interleukin 6, produced by mesenchymal...
3.
Paino T, Gonzalez-Mendez L, San-Segundo L, Corchete L, Hernandez-Garcia S, Diaz-Tejedor A, et al.
Cancers (Basel)
. 2020 Sep;
12(10).
PMID: 32987735
Background: Proviral Insertion site for Moloney murine leukemia virus (PIM) kinases are overexpressed in hematologic malignancies, including multiple myeloma. Previous preclinical data from our group demonstrated the anti-myeloma effect of...
4.
Algarin E, Diaz-Tejedor A, Mogollon P, Hernandez-Garcia S, Corchete L, San-Segundo L, et al.
Haematologica
. 2019 Jul;
105(3):e116-e120.
PMID: 31320555
No abstract available.
5.
Hernandez-Garcia S, San-Segundo L, Gonzalez-Mendez L, Corchete L, Misiewicz-Krzeminska I, Martin-Sanchez M, et al.
Haematologica
. 2017 Sep;
102(12):2113-2124.
PMID: 28860344
Kinesin spindle protein inhibition is known to be an effective therapeutic approach in several malignancies. Filanesib (ARRY-520), an inhibitor of this protein, has demonstrated activity in heavily pre-treated multiple myeloma...
6.
Lopez-Iglesias A, Herrero A, Chesi M, San-Segundo L, Gonzalez-Mendez L, Hernandez-Garcia S, et al.
J Hematol Oncol
. 2017 Jun;
10(1):127.
PMID: 28633670
Background: Despite recent advances in the treatment of multiple myeloma (MM), the prognosis of most patients remains poor, and resistance to traditional and new drugs frequently occurs. EDO-S101 is a...
7.
Lopez-Iglesias A, Gonzalez-Mendez L, San-Segundo L, Herrero A, Hernandez-Garcia S, Martin-Sanchez M, et al.
Haematologica
. 2016 Aug;
102(1):168-175.
PMID: 27540138
Despite new advances in multiple myeloma treatment and the consequent improvement in overall survival, most patients relapse or become refractory to treatment. This suggests that new molecules and combinations that...
8.
Paino T, Garcia-Gomez A, Gonzalez-Mendez L, San-Segundo L, Hernandez-Garcia S, Lopez-Iglesias A, et al.
Clin Cancer Res
. 2016 Jul;
23(1):225-238.
PMID: 27440267
Purpose: PIM kinases are a family of serine/threonine kinases recently proposed as therapeutic targets in oncology. In the present work, we have investigated the effects of the novel pan-PIM kinase...